Search PubMed⌕ Search

Biomedical subjects

T Hudson

Publications and source records attributed to T Hudson.

At least 19 recordsLinked to original sources
PubMed1996

Buyouts & ventures. Selling ... or selling out.

Charity begins at home, yet across the country hometown not-for-profit hospitals are forming joint partnerships with investor-owned systems. In some of these cases no foundation is created to continue the hospital's good deeds. In this special report, Hospitals & Health Networks looks at the issues and asks, "Do these joint ventures need more public scrutiny?"

Charities↗
PubMed1996

Mirror, mirror ... on the wall, who are the healthiest Americans of all?

The Dartmouth Atlas of Health Care puts a human face on how this country's precious health care resources are divvied up--market by market by market. Dr. John Wennberg spent 30 years researching the project, and the end result may profoundly influence how patients are treated in the future. But in holding up a mirror to the American health care system, does the atlas pose more questions than it answers?

Atlases as Topic↗
PubMed1996

There's no place like home.

When the school system in tiny Colby, Kans., signed onto a health plan that excluded the only hospital in the entire county, its citizens learned an important lesson. ¿If we're not working together,¿ says the hospital's administrator, ¿health plans and medical centers are going to come in here and take business away from us.¿ Here's what they learned about keeping rural health care rural.

Community Health Planning↗
PubMed1996

Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention.

The common dietary constituent quercetin was a potent inhibitor of sulfoconjugation of acetaminophen and minoxidil by human liver cytosol, partially purified P-form phenolsulfotransferase (PST), and recombinant P-form PST, with IC50 values of 0.025-0.095 microM. Quercetin inhibition of acetaminophen was noncompetitive with respect to acceptor substrate, with a Ki value of 0.067 microM. A number of other flavonoids, such as fisetin, galangin, myricetin, kaempferol, chrysin, and apigenin, were also potent inhibitors of P-form PST-mediated sulfation, with IC50 values < 1 microM. Studies of structural analogs indicated the flavonoid 7-hydroxyl group as particularly important for potent inhibition. Potential human metabolites of quercetin were poor inhibitors. Curcumin, genistein, and ellagic acid (other polyphenolic natural products) were also inhibitors of P-form PST, with IC50 values of 0.38-34.8 microM. Quercetin was also shown to inhibit sulfoconjugation by the human hepatoma cell line Hep G2. Although less potent in this intact cell system (IC50 2-5 microM), quercetin was still more potent than 2,6-dichloro-4-nitrophenol, the classical P-form PST inhibitor that has been shown to be an inhibitor also in vivo. These observations suggest the potential for clinically important drug interactions, as well as a possible role for flavonoids as chemopreventive agents in sulfation-induced carcinogenesis.

Arylsulfotransferase↗
PubMed1995

Ex-hospital CEOs. Where are they now?

One former hospital executive says his friends tell him he looks years younger. Another says he wanted to make more money, and now he can. And yet another says she wanted to start her own company before she was too old to enjoy it. These and other ex-CEOs left powerful positions, not to mention fancy corner offices, for an uncertain future. As it turns out, they're happier than ever. What do they know that you don't?

Career Mobility↗